IL10 and colitis: Interestingly, after SPX, the treatment with α7 agonist lost completely its protective effects against colitis, being unable to lower IL-1β concentrations and exacerbating TNBS-induced increase of IL-6 levels, while leaving unmodified IFNγ and IL-10 colonic content with respect to SPX/C mice (Figure 6).